<DOC>
	<DOCNO>NCT00034125</DOCNO>
	<brief_summary>To determine safety efficacy LY353381 compare tamoxifen woman advance metastatic breast cancer .</brief_summary>
	<brief_title>Phase 3 Study LY353381 Vs Tamoxifen Women With Locally Advanced Metastatic Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Inclusion Criteria 1 . Locally advanced metastatic breast cancer 2 . Bidimensionally measurable disease Exclusion Criteria 1 . Prior hormonal therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>cancer</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>hormonal therapy</keyword>
</DOC>